PPAR-γ Impairment Alters Peroxisome Functionality in Primary Astrocyte Cell Cultures
Figure 6
Hydrogen peroxide levels: effect of G3335. Astrocytes (5 105 cells/well) were treated with the reversible PPARγ antagonist G3335 (30 μM) for 2 days or 5 days, in the absence or presence of the PPARγ agonist rosiglitazone (100 μM). Values are expressed as the mean ± S.E.M. percent of control of three experiments. Control condition was arbitrarily set as 100%. * in comparison to control conditions in the absence of treatment; in comparison to G3335 treatment on days 2 or 5.
